ClinicalTrials.gg
CompletedNCT06574035MenDIIIUpdated Oct 9, 2026

Michigan Men's Diabetes Project III(MenDIII): Mind and Motion

An interventional study of Cognitive Behavioral Therapy and Exercise in Diabetes Mellitus, Type 2, Depressive Symptoms and Depression, sponsored by University of Michigan. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by University of Michigan · Not applicable, Interventional, and Health services research

How we know

Updated Oct 9, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan — 5 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Michigan.

Enrollment
31st of 36
19 · median 48
Started
2025
the only one that year
No phase
31 of 38
3 open now
Registered
37th of 38
by date

Among the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, this one is the 31st largest by enrollment of the 36 interventional ones that give a count, is the only one that started in 2025, is one of 31 with no phase, and was the 37th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 38 studies in Diabetes Mellitus, Type 2 by University of Michigan are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 38 studies in Diabetes Mellitus, Type 2 by University of Michigan, or all of them as a file.
02

Study summary

The Michigan Men's Diabetes Project III: Mind \& Motion is an 7-month pilot randomized clinical trial. The investigators are looking to recruit 80 Black men with type 2 diabetes (T2D) (need to have diagnosis for at least one year) that are over the age of 18. Participants also must be under the care of a physician for their diabetes, self report an Hemoglobin A1c (A1C) of 7.0% or more in the last year, be willing to participate in study events (weekly physical activity, exercise and Cognitive Behavioral Therapy (CBT) sessions, group discussion sessions, and in-person health assessments), have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet/phone/computer to complete study related tasks, live in the Wayne or Washtenaw County, and have reliable transportation to in-person events. All participants will receive 8 hours/sessions of cognitive behavioral therapy. Participants randomized to the intervention arm will also receive 8 sessions of guided exercise at the same time. Following that they will also receive 8 group discussion sessions that will serve as on-going support. All sessions will be help via Zoom. Additionally, all participants will participate in The 4 health assessments will take place at baseline, 10 weeks, 18 weeks, and 30 weeks.

03

Conditions studied

  • Diabetes Mellitus, Type 2
  • Depressive Symptoms
  • Depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • African American/Black males
  • age 18 years or older
  • ambulatory status
  • diagnosis of Type 2 Diabetes (T2D) for one year duration or longer
  • be under the care of a physician for their diabetes, self report an of 7.0% or more in the last year
  • be willing to participate in study events (weekly physical activity, exercise and CBT sessions, group discussion sessions, and in-person health assessments)
  • have reliable internet access (steady internet connection or unlimited data) that will allow them to use a tablet/phone/computer to complete study related tasks
  • live in the Wayne or Washtenaw County\
  • have reliable transportation to in-person events

Exclusion criteria

Exclusion Criteria:

  • stage 2 hypertension as defined by Joint National Committee (JNC) VIII
  • recent cardiac events
  • recent laser surgery for proliferative retinopathy
  • history of stroke
  • lower limb amputation
  • peripheral neuropathy
  • severe (COPD) (e.g., basal oxygen)
  • class III or IV heart failure
  • medical instability.

Per American College of Sports Medicine (ACSM) guidelines, medical exclusion criteria will also include currently experiencing:

  • ongoing unstable angina
  • uncontrolled cardiac arrhythmia with hemodynamic compromise
  • active endocarditis
  • symptomatic severe aortic stenosis
  • acute myocarditis or pericarditis
  • acute aortic dissection
  • acute pulmonary embolism
  • pulmonary infarction
  • deep venous thrombosis
  • physical disability that precludes safe and adequate testing
  • chest discomfort with exertion
  • unreasonable breathlessness, or dizziness, fainting, or blackouts.

As part of the screening process, the investigators will ask the participant to self-report on these conditions. Participants who are currently receiving psychotherapy services for the treatment of depression from a mental health provider will be excluded. Participants who are currently receiving only medication management from a psychiatrist will be included.

If you are interested in the study, please complete our screening survey: https://redcapproduction.umms.med.umich.edu/surveys/?s=JNPPEDANX7KLPPF9. Thank you so much!

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Intervention Group

    Participants randomized to the intervention group will receive 8 one hour virtual sessions of individual cognitive behavioral therapy (CBT) that will take place via U-M Zoom, which is a HIPAA compliant virtual conferencing platform. Participants in this group will also receive 8 one hour virtual sessions of individual exercise. Participants in this group will also receive 8 one hour virtual group discussion sessions that will serve as on-going support. This group (4-8 participants) discussion will be facilitated by one CBT Interventionist and one Exercise Interventionist. These sessions will take place following the individual sessions of CBT and Exercise.

    Behavioral: Cognitive Behavioral Therapy · Behavioral: Exercise · Behavioral: Group Discussions - Ongoing Support

  • Active comparator
    Control Group

    Participants randomized to the control group will receive enhanced usual care (EUC). The EUC group will receive 8 sessions of standard Cognitive Behavioral Therapy.

    Behavioral: Cognitive Behavioral Therapy

Interventions

  • BehavioralCognitive Behavioral Therapy

    Cognitive behavioral therapy focuses on the unique needs of men. A culturally adapted CBT program will be administered to participants as it has demonstrated increased effectiveness for marginalized populations. Cognitive Behavioral Therapy (CBT) aligns well with these cultural needs due to its individualized approach, non-judgmental stance, collaborative nature, and emphasis on empowerment through skills building.

  • BehavioralExercise

    Research demonstrates a preference for physical activity interventions among men with chronic illnesses, while highlighting limited access to fitness facilities in low-income urban areas as a barrier to participation. Online physical activity interventions have shown efficacy and cost-effectiveness in improving health behaviors, with virtual exercise programs for low-income African American populations demonstrating significant reductions in depressive symptoms. Therefore participants will receive exercise to help improve their diabetes self-management behaviors and depressive symptoms.

  • BehavioralGroup Discussions - Ongoing Support

    Participants will join group discussions that will serve as on-going support. The small group component is designed to foster self-efficacy, autonomous motivation, and enjoyment by integrating skills building, personal values, spirituality, and goal setting. This approach has shown positive outcomes in previous pilot studies with African American men, serving as a source of vicarious learning and social support.

06

What researchers measure

Primary outcomes

  1. Change in A1C

    Anthropometric/clinical data

    Time frame: Screening, Baseline, 10 weeks, 18 weeks, 30 weeks

  2. Change in General Quality of Life (12-Item Short Form Survey (SF-12))

    Survey Data - 12 questions covering physical and mental health domains - Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  3. Change in Diabetes-Related Distress (The Type 2 Diabetes Distress Assessment System)

    Survey Data - The assessment system has two components: The Core Distress Scale and The Sources Scale. The CORE DISTRESS SCORE is simply the average of the 8 items of the CORE SCALE, with each item rated on a 1 to 5 scale: Mean score \< 2.0 indicate little or no distress, Mean score between 2.0 and 2.9 indicate moderate distress, Mean score \> 3.0 indicate high distress. The Sources scale aims to find the sources of the distress, whether CORE DISTRESS is high or low, it is helpful to identify those aspects of living with diabetes that are contributing to the individual's diabetes distress.

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  4. Change in Diabetes Quality of Life (Diabetes Quality of Life Instrument)

    Survey Data - Survey answers range for each section of the survey asking about satisfaction, worry, and impact of diabetes. The DQoL measure consists of 46 items ranked on a 5-point Likert scale. Individual domain and DQoL total scores range from 0 (lowest possible QoL) to 100 (highest possible QoL).

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

Secondary outcomes

  1. Change in Diabetes Self-Efficacy (Perceived Diabetes Self-Management Scale)

    Survey Data - The scale is an 8-item scale that uses a 5-point Likert scale to measure self-efficacy in diabetes management. The scale ranges from 8 to 40 points, with higher scores indicating greater self-efficacy.

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

Other outcomes

  1. Change in Masculinity Ideology (The Conformity to Masculine Norms Inventory-30)

    Survey Data - The CMNI-30's subscales are scored by adding up the scores of each item. It is a 30-item scale that measures how much a person conforms to masculine norms in US society. The items are rated on a six-point Likert scale, ranging from 0 (strongly disagree) to 5 (strongly agree), with nine items reverse-coded.

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  2. Change in BMI

    Anthropometric/clinical data

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  3. Chance in Estimated Abdominal Subcutaneous and Visceral Fat Stores

    Anthropometric/clinical data

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  4. Change in Diabetes Social Support (Duke/UNC Functional Social Support)

    Survey Data - Responses are scaled on a 1-5 scale and tallied to create a total score with higher values indicating greater social support.

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  5. Sociodemographic characteristics

    Survey Data

    Time frame: Baseline

  6. Healthcare utilization

    Survey Data

    Time frame: Baseline

  7. Comorbidities

    Survey Data

    Time frame: Baseline

  8. Change in Medication Adherence (Adherence to Refills and Medicines Scale for Diabetes)

    Survey Data - The scale a 14-question survey that measures self-reported medication adherence. The ARMS-D is designed to be brief and easy to use, and can help identify reasons for non-adherence. Each item on the scale is rated on a four-point Likert scale, with 1 being "none of the time" and 4 being "all of the time". The items are then summed to create a score that ranges from 11 to 44, with higher scores indicating better adherence.

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  9. Change in Aerobic Capacity (6 minute walk test)

    Anthropometric/clinical data

    Time frame: Baseline, 10 weeks, 30 weeks

  10. Change in Working Alliance between Counselor & Participant (Working Alliance Inventory - Short Revised)

    Survey Data - The Scale is 12 questions, Each item is scored from 1-7, minimum=1 to maximum=7, ranging from Never to Always. Higher scores reflect a more positive rating of working alliance.

    Time frame: Up to 8 weeks

  11. Change in Metabolic Control (continuous blood glucose levels)

    Anthropometric/clinical data

    Time frame: Up to 18 weeks

  12. Change in Depression Symptoms (Patient Health Questionnaire 9)

    Survey Data - Answer Options rang from Not at all = 0, Several days = 1, More than half the days = 2, Nearly every day = 3. Scores can range from 1 - 27, the higher the score, the more severe the depression.

    Time frame: Screening and throughout study completion, up to 30 weeks.

  13. Change in Blood Pressure (systolic and diastolic)

    Anthropometric/clinical data

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

  14. Change in Physical Activity Regimen

    Exercise Log Data

    Time frame: Up to 18 weeks

  15. Change in Heart Rate

    Anthropometric/clinical data

    Time frame: Baseline, 10 weeks, 18 weeks, 30 weeks

07

Study locations

1 site
  • University of Michigan
    Ann Arbor, Michigan 48109, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Aug 2026, 19 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 19 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: primary completion Sep 2026 → Aug 2026 and completion Sep 2026 → Aug 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 27, 2024
StartActual
Jan 13, 2025
Primary completionActual
Aug 28, 2026was Sep 2026
CompletionActual
Aug 28, 2026was Sep 2026
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Oct 9, 2026
Primary completion
Sep 2026→Aug 28, 2026 (actual)
Oct 9, 2026
Study completion
Sep 2026→Aug 28, 2026 (actual)
Oct 9, 2026
Enrollment
80 (estimated)→19 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Recruiting→Completed
    Primary completion Sep 2026→Aug 28, 2026 (now actual)
    Study completion Sep 2026→Aug 28, 2026 (now actual)
    Enrollment 80 (estimated)→19 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06574035
Responsible party
Jaclynn Hawkins (Assistant Professor, University of Michigan) — Principal investigator
First posted
Aug 27, 2024
Start date
Jan 13, 2025
Primary completion
Aug 28, 2026
Completion
Aug 28, 2026
Last update
Oct 9, 2026

Study contacts

Jaclynn Hawkins, PhD
principal investigator · University of Michigan, School of Social Work

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion